Home / Market News / $PFE
benzinga Corporate Catalyst Impact 65/100 ● positive

Pfizer Announces Its Two Phase 3 Studies Of LITFULO Demonstrate TRANQUILLO 2 and TRANQUILLO, LITFULO Enhance Facial, Total Body Repigmentation Compared To Placebo; Co. Plans To File Data to Regulatory Authorities Globally, Include FDA And European Medicines Agency

Oct 2, 2026, 3:19 PM UTC · Primary ticker $PFE

Pfizer announced positive Phase 3 trial results for LITFULO in treating vitiligo, demonstrating significant facial and total body repigmentation compared to placebo. This data will be submitted to global regulatory authorities, positioning LITFULO as a potential new oral treatment for nonsegmental vitiligo.

Pfizer presented positive results from two Phase 3 trials (TRANQUILLO 2 and TRANQUILLO) for its drug LITFULO (ritlecitinib) in treating nonsegmental vitiligo. The studies showed significant improvements in facial and total body repigmentation compared to placebo, supported by patient-reported outcomes. This is a positive development for Pfizer as it indicates a strong potential for LITFULO to become a new oral systemic therapy for vitiligo, a condition with limited treatment options. The company plans to submit these data to regulatory authorities globally, including the FDA and EMA, which could lead to market approval and a new revenue stream for Pfizer in the long term. For traders, this represents an opportunity for PFE stock appreciation as the drug moves closer to commercialization, though the immediate impact might be moderate as regulatory approval is still pending.

$PFE positive Successful Phase 3 trial results for key drug candidate
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.